APA Zitierstil

Ridge, T., Moretto, T., MacConell, L., Pencek, R., Han, J., Schulteis, C., & Porter, L. (2012). Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Blackwell Publishing Ltd.

Chicago Zitierstil

Ridge, T., T. Moretto, L. MacConell, R. Pencek, J. Han, C. Schulteis, und L. Porter. Comparison of Safety and Tolerability With Continuous (exenatide Once Weekly) or Intermittent (exenatide Twice Daily) GLP-1 Receptor Agonism in Patients With Type 2 Diabetes. Blackwell Publishing Ltd, 2012.

MLA Zitierstil

Ridge, T., et al. Comparison of Safety and Tolerability With Continuous (exenatide Once Weekly) or Intermittent (exenatide Twice Daily) GLP-1 Receptor Agonism in Patients With Type 2 Diabetes. Blackwell Publishing Ltd, 2012.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.